Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
PYXS Stock Summary
In the News

Pyxis Oncology to Present at H.C. Wainwright Preclinical Cancer Drug Discovery Conference
CAMBRIDGE, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), an oncology company focused on developing next-generation therapeutics for difficult-to-treat cancers, today announced that the Company will present at the H.C. Wainwright Preclinical Cancer Drug Discovery - Antibody Drug Conjugates (ADCs) virtual conference. The pre-recorded presentation given by Lara Sullivan, M.D., President and Chief Executive Officer, and Jay Feingold, M.D., Ph.D., Chief Medical Officer, will be available on-demand at 9:00 a.m. ET on Wednesday, June 29, 2022.

Pyxis Oncology Announces Presentations at Upcoming Investor Conferences
CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat cancers, today announced that Lara Sullivan, M.D., President and Chief Executive Officer, and members of the management team will present at the following upcoming investor conferences:

Pyxis Oncology to Host Corporate Update Conference Call and Webcast on March 29, 2022
CAMBRIDGE, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset, multi-modality company focused on developing next-generation therapeutics for difficult to treat cancers, today announced it will host a conference call and live webcast on Tuesday, March 29, 2022 at 8:00 a.m. ET to discuss recent corporate updates.

Pyxis Oncology to Present at the Jefferies London Healthcare Conference
CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), today announced that management will present at and host one-on-one investor meetings during the virtual portion of the Jefferies London Healthcare Conference, taking place November 18-19, 2021. The presentation will be available on-demand for attendees during the virtual conference beginning on November 18, 2021. A replay of the presentation will be available on the Events and Presentation page on Pyxis Oncology's website following the conference's conclusion.
PYXS Financial details
PYXS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | |
Net income per share | -0.13 | -0.58 | -8.95 | 0 | |
Operating cash flow per share | -0.1 | -0.46 | -4.16 | -2.7 | |
Free cash flow per share | -0.1 | -0.53 | -4.22 | -2.9 | |
Cash per share | 0.9 | 0.37 | 32.35 | 5.43 | |
Book value per share | -0.13 | -0.71 | 30.77 | 4.87 | |
Tangible book value per share | -0.13 | -0.71 | 30.77 | 4.87 | |
Share holders equity per share | -0.13 | -0.71 | 30.77 | 4.87 | |
Interest debt per share | 0 | 0.04 | 0.02 | 0.57 | |
Market cap | 290.07M | 290.07M | 93.17M | 44.26M | |
Enterprise value | 270.4M | 282.77M | -181.56M | -116.11M | |
P/E ratio | -104.64 | -22.61 | -1.23 | 0 | |
Price to sales ratio | 0 | 0 | 0 | 0 | |
POCF ratio | -129.56 | -28.77 | -2.64 | -0.5 | |
PFCF ratio | -129.56 | -25.08 | -2.6 | -0.46 | |
P/B Ratio | -100.93 | -18.54 | 0.36 | 0.28 | |
PTB ratio | -100.93 | -18.54 | 0.36 | 0.28 | |
EV to sales | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -97.55 | -22.88 | 2.41 | 0.95 | |
EV to operating cash flow | -120.77 | -28.04 | 5.14 | 1.3 | |
EV to free cash flow | -120.77 | -24.45 | 5.06 | 1.21 | |
Earnings yield | -0.01 | -0.04 | -0.82 | 0 | |
Free cash flow yield | -0.01 | -0.04 | -0.38 | -2.16 | |
Debt to equity | -7.89 | -1.65 | 0.07 | 0.31 | |
Debt to assets | 1.15 | 2.54 | 0.07 | 0.24 | |
Net debt to EBITDA | 7.1 | 0.59 | 3.65 | 1.31 | |
Current ratio | 26.88 | 2.2 | 14.9 | 5.9 | |
Interest coverage | 0 | 0 | 0 | 0 | |
Income quality | 0.81 | 0.79 | 0.46 | 0.74 | |
Dividend Yield | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0.15 | 0.02 | 0.07 | |
Capex to revenue | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | -3.16 | -0.83 | -9.03 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | |
Graham number | 0.61 | 3.06 | 78.69 | 0 | |
ROIC | 0.14 | 1.82 | 0.25 | 0 | |
Return on tangible assets | -0.14 | -1.26 | -0.27 | 0 | |
Graham Net | -0.14 | -0.81 | 30.14 | 3.9 | |
Working capital | 18.97M | 4.41M | 259.97M | 154.98M | |
Tangible asset value | -2.87M | -15.65M | 261.31M | 160.82M | |
Net current asset value | -2.98M | -17.69M | 259.97M | 136.06M | |
Invested capital | -0.01 | -0.05 | 0 | 0.12 | |
Average receivables | 0 | 0 | 0 | 0 | |
Average payables | 0 | 784K | 6.51M | 9.52M | |
Average inventory | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | |
ROE | 0.96 | 0.82 | -0.29 | 0 | |
Capex per share | 0 | -0.07 | -0.06 | -0.19 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q4
Metric | History | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -1.85 | -0.97 | 0 | -0.85 | 0 | |
Operating cash flow per share | -0.8 | -0.86 | -0.73 | -0.63 | -2.08 | |
Free cash flow per share | -0.81 | -0.86 | -0.73 | -0.76 | -2.15 | |
Cash per share | 8.66 | 7.65 | 6.88 | 6.1 | 5.43 | |
Book value per share | 8.23 | 7.23 | 6.53 | 5.8 | 4.87 | |
Tangible book value per share | 8.23 | 7.23 | 6.53 | 5.8 | 4.87 | |
Share holders equity per share | 8.23 | 7.23 | 6.53 | 5.8 | 4.87 | |
Interest debt per share | 0.01 | 0 | 0.48 | 0.52 | 0.57 | |
Market cap | 348.12M | 130.56M | 77.23M | 64.15M | 44.26M | |
Enterprise value | 73.39M | -116.53M | -130.44M | -118.34M | -116.11M | |
P/E ratio | -1.48 | -1.04 | 0 | -0.58 | 0 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -13.71 | -4.72 | -3.26 | -3.12 | -0.64 | |
PFCF ratio | -13.5 | -4.69 | -3.24 | -2.58 | -0.62 | |
P/B Ratio | 1.33 | 0.56 | 0.36 | 0.34 | 0.28 | |
PTB ratio | 1.33 | 0.56 | 0.36 | 0.34 | 0.28 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -1.26 | 3.73 | 5.1 | 4.42 | 1.23 | |
EV to operating cash flow | -2.89 | 4.21 | 5.5 | 5.76 | 1.69 | |
EV to free cash flow | -2.85 | 4.19 | 5.47 | 4.77 | 1.64 | |
Earnings yield | -0.17 | -0.24 | 0 | -0.43 | 0 | |
Free cash flow yield | -0.07 | -0.21 | -0.31 | -0.39 | -1.6 | |
Debt to equity | 0.07 | 0.08 | 0.14 | 0.19 | 0.31 | |
Debt to assets | 0.07 | 0.08 | 0.13 | 0.16 | 0.24 | |
Net debt to EBITDA | 4.71 | 7.92 | 8.12 | 6.82 | 1.7 | |
Current ratio | 14.9 | 13.1 | 15.19 | 10.62 | 5.9 | |
Interest coverage | 0 | -3.49K | 0 | -39.49 | 0 | |
Income quality | 0.43 | 0.88 | 0.93 | 0.74 | 0.74 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.02 | 0.01 | 0.01 | 0.21 | 0.03 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -1.83 | -0.92 | -0.81 | -21.33 | -4.19 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 18.5 | 12.56 | 0 | 10.53 | 0 | |
ROIC | 0.06 | 0.13 | 0 | 0.16 | 0 | |
Return on tangible assets | -0.21 | -0.12 | 0 | -0.12 | 0 | |
Graham Net | 8.07 | 7.05 | 5.94 | 5.02 | 3.9 | |
Working capital | 259.97M | 232.07M | 211.68M | 183.71M | 154.98M | |
Tangible asset value | 261.31M | 233.51M | 211.97M | 188.75M | 160.82M | |
Net current asset value | 259.97M | 232.07M | 196M | 167.66M | 136.06M | |
Invested capital | 0 | 0 | 0.07 | 0.09 | 0.12 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 6.94M | 7M | 4.94M | 6.66M | 6.3M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.22 | -0.13 | 0 | -0.15 | 0 | |
Capex per share | -0.01 | 0 | 0 | -0.13 | -0.06 |
PYXS Frequently Asked Questions
What is Pyxis Oncology, Inc. stock symbol ?
Pyxis Oncology, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol PYXS
What is Pyxis Oncology, Inc. stock quote today ?
Pyxis Oncology, Inc. stock price is $2.21 today.
Is Pyxis Oncology, Inc. stock public?
Yes, Pyxis Oncology, Inc. is a publicly traded company.